|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|
| OPERATING ACTIVITIES | |
| Net loss | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |
| Depreciation and amortization | |
| Unit-based compensation expense | |
| Amortization of debt issuance cost | |
| Change in fair value of derivative liabilities | |
| Change in fair value of warrant liabilities | |
| Change in operating assets and liabilities: | |
| R&D tax credit receivable | |
| Prepaid and other current assets | |
| Inventory | |
| Long term assets | |
| Accounts payable | |
| Accrued liabilities | |
| Accrued compensation | |
| Accrued federal tax liability, penalties and interest | |
| Interest payable | |
| Interest payable to related parties | |
| Deferred revenue | |
| Payable to related parties | |
| Net cash used in operating activities | |
| INVESTING ACTIVITIES | |
| Purchases of property, plant and equipment | |
| Net cash used in investing activities | |
| FINANCING ACTIVITIES | |
| Proceeds from loans | |
| Loan origination fees | |
| Adjustment to shareholder receivables | |
| Net cash provided by financing activities | |
| Net (decrease) increase in cash during period | |
| Cash, beginning of period | |
| Cash, end of period | |
| SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES | |
| 349,871 series B units transferred from NACS to Taylor Freres |
Loading...
